United Therapeutics Corporation
UTHR
$284.73
-$0.46-0.16%
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Net Income | 1.20B | 1.11B | 1.07B | 1.05B | 984.80M |
Total Depreciation and Amortization | 72.50M | 66.50M | 60.70M | 54.90M | 53.20M |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 119.70M | 106.90M | 90.20M | 59.50M | 37.80M |
Change in Net Operating Assets | -60.20M | -147.70M | -114.70M | -185.20M | -97.80M |
Cash from Operations | 1.33B | 1.14B | 1.11B | 979.70M | 978.00M |
Capital Expenditure | -246.50M | -238.50M | -227.70M | -227.30M | -230.40M |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -89.20M | -89.20M | -89.20M | -89.20M |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 663.70M | 910.20M | 700.90M | 553.30M | -400.00M |
Cash from Investing | 417.20M | 582.50M | 384.00M | 236.80M | -719.60M |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -400.00M | -400.00M | -300.00M | -200.00M | -100.00M |
Issuance of Common Stock | 160.10M | 141.80M | 113.30M | 85.90M | 104.60M |
Repurchase of Common Stock | -1.01B | -1.01B | -1.01B | -1.01B | -13.80M |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -2.70M | -2.70M | -2.70M | -2.70M | -2.70M |
Cash from Financing | -1.25B | -1.27B | -1.20B | -1.13B | -11.90M |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 489.50M | 446.20M | 288.40M | 88.00M | 246.50M |